Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Adicet Bio, Inc. (TORC) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 REDWOOD CITY, Calif. & BOSTON – August 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023. &#x..."
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Adicet Announces Appointment of Katie Peng to the Board of Directors REDWOOD CITY, Calif. & BOSTON – July 11, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors. “We are delighted to welcome Katie to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Her proven success as a commercial leader in both the U.S. and globally will be particularly valuable to Adicet as we advance ADI-001 and our pipeline of allogeneic gamma delta T cell therapy candidates in hematologic and solid tumors.” “I am pleased to join the Adicet Board at this exciting time for th..."
06/29/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 15.5% stake in Adicet Bio, Inc.
06/05/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SIXTH AMENDMENTTO"
05/18/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy 26th Annual Meeting ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and durability within a solid tumor microenvironment ADI-270 demonstrated potent anti-tumor activity in CD70+ cancers and improved resilience to clearance from host immune targeting REDWOOD CITY, Calif. & BOSTON – May 18, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet with $231.6 million in cash, cash equivalents and investments as of March 31, 2023 Redwood City, Calif. and BOSTON – May 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023. “We are excited about the continued clinical progress of our lead asset ADI-001,” said Chen Schor, President and Chief Executive Officer of Adicet. “In the s..."
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress • Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma ; Next data update expected in Q2 2023 • Announced preclinical data for differentiated chimeric antigen receptor and chimeric adaptor programs at The Society for Immunotherapy of Cancer 37th Annual Meeting and Adicet’s R&D Pipeline Event REDWOOD CITY, Calif. and BOSTON – March 15, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and ye..."
03/13/2023 SC 13G TANG CAPITAL PARTNERS LP reports a 5.3% stake in Adicet Bio, Inc.
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 5 Schor Chen (President & CEO) has filed a Form 5 on Adicet Bio, Inc.
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in ADICET BIO, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/11/2023 SC 13G/A Cowen Financial Products LLC reports a 7.3% stake in Adicet Bio Inc.
12/22/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/12/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1study during ASH Annual Meeting Company to host ADI-001 webcast event on December 11, 2022 at 9:00 a.m. ET On track to initiate a potentially pivotal program for ADI-001 in the first half of 2023 Strong balance sheet with $282.7 million in cash and cash equivalents as of September 30, 2022; Cash runway into first half of 2025 Company to host R&D webcast event detailing four new pipeline candidates on November 10, 2022 at 9:00 a.m. ET REDWOOD CITY, Calif. and BOSTON – November 8, 2022 – Adicet Bio, Inc. , a clinical stage biotechnology company discoverin..."
11/03/2022 8-K Quarterly results
10/17/2022 SC 13G RA CAPITAL MANAGEMENT, L.P. reports a 5.5% stake in ADICET BIO, INC.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy